Last Price
0.595
Today's Change
-0.01 (1.65%)
Day's Change
0.58 - 0.644
Trading Volume
45,283
Market Cap
7 Million
Shares Outstanding
11 Million
Avg Volume
962,612
Avg Price (50 Days)
0.68
Avg Price (200 Days)
0.98
PE Ratio
-0.29
EPS
-2.05
Earnings Announcement
04-Oct-2024
Previous Close
0.61
Open
0.59
Day's Range
0.58 - 0.644
Year Range
0.5 - 6.41
Trading Volume
45,642
1 Day Change
-1.70%
5 Day Change
-3.72%
1 Month Change
-0.67%
3 Month Change
-16.20%
6 Month Change
-49.15%
Ytd Change
-55.93%
1 Year Change
-67.49%
3 Year Change
-95.96%
5 Year Change
-95.96%
10 Year Change
-95.96%
Max Change
-95.96%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.